Elraglusib
As of the edition of 20 October 2026, Elraglusib is a small molecule: in active development; acts on GSK3B.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Small molecule
- Registered trials
- 11, 5 stopped early
- Disease areas
- Cancer; Nervous system; Bones, joints and muscles; Inherited and neonatal; Blood and lymph; Mouth and teeth
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| GSK3B | Glycogen synthase kinase-3 beta | P49841 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 0 | 1 | 1 |
| Phase 2 | 9 | 1 | 4 | 4 |
| All trials | 11 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Actuate Therapeutics | Lead sponsor of trials | 2019 to now |